Temple Health Chest Initiative (THCI 2.0)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-80
SponsorTemple University

About this trial

Chronic obstructive pulmonary disease is highly prevalent globally, with considerable morbidity and mortality associated. In the US, it is the 4th leading cause of death, as well as contributing to significant costs on healthcare utilization including hospitalization. Population-based screening for COPD has not been recommended by the US Preventative Services Task Force (USPSTF). However, LDCT screening for lung cancer in patients aged 50- 80 with ≥ 20 pack year smoking has been shown to improve survival. COPD is highly prevalent within LCS programs, with estimated rates of obstructive lung function of up to 59% and evidence of emphysema on CT scan in around 70%.

Eligibility criteria

Qualifiers

50 to 80 years old

Screened for early lung cancer using low dose CT imaging

Disqualifiers

Under 50; over 80 years old

No lung cancer screening

Trial design

Treatments tested in this trial

  • Determine COPD prevalence utilizing spirometry along with CT scans and symptom assessments in the THCI lung cancer screening populatio

Treatment groups

1,000 Participants
are divided into 1 treatment group

Sponsors and collaborators